<DOC>
	<DOCNO>NCT00417209</DOCNO>
	<brief_summary>The purpose study compare efficacy safety Larotaxel administer single agent every 3 week continuous administration 5-FU every 3 week , patient advance pancreatic cancer ( non operable curative intent , locally recurrent metastatic ) previously treat gemcitabine base therapy .</brief_summary>
	<brief_title>Larotaxel Compared To Continuous Administration 5-FU Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Advanced ( non operable curative intent , locally recurrent metastatic disease ) Cytologically histologically proven epithelial cancer ( adenocarcinoma ) exocrine pancreas . Patient must previously treat systemic gemcitabine base regimen Adequate bone marrow , kidney liver function ECOG performance status ( PS ) 234 . Prior locoregional radiotherapy pancreatic cancer . Symptomatic brain metastasis leptomeningeal disease . Any serious intercurrent infection , uncontrolled cardiac gastrointestinal disease . Other concurrent malignancy Other protocoldefined exclusion/inclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>advanced pancreatic cancer</keyword>
</DOC>